The government proposed new rules Wednesday to make it easier for doctors and patients to learn if clinical trials of treatments worked or not. Thousands of Americans participate in clinical trials every year, testing new treatments, comparing old ones or helping to uncover general knowledge about health. Many of the studies are reported in scientific journals and trumpeted in the news.
Univ. of California, Los Angeles biochemists have created the largest-ever protein that self-...
A coalition of companies and aid groups announced plans Tuesday to test experimental drugs and...
Health workers on the front line of the Ebola crisis say the need for urgent help isn't letting up, as Congress begins considering President Barack Obama's $6.2 billion emergency aid request to fight the disease. Despite reports that the number of infections is slowing in some parts of West Africa, cases still are rising in other areas.
A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a recent pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long lasting, which could have significant global implications in controlling future outbreaks.
European Union nations are working to reach 1 billion euros ($1.27 billion) in aid by the end of the week to fight Ebola in West Africa and are seeking a common approach to the crisis.EU foreign ministers began a week of talks Monday so their 28 leaders can agree by Friday on better measures to fight Ebola, anything from financial aid to common repatriation procedures, more Ebola treatment facilities and better training for health workers.
The new Urban Dynamics Institute at Oak Ridge National Laboratory is working with the Bill & Melinda Gates Foundation to aid polio vaccination efforts in developing countries. Teams at the institute will apply big data analysis to population dynamics in Nigeria, allowing polio vaccination crews to better estimate the amount of vaccine needed and to target areas of priority, saving time and money in eradicating the disease.
The Centers for Disease Control and Prevention has said that at least 2 million Americans are sickened by antibiotic resistant infections each year and survive. Twenty-three thousand die. These experiences leave deep impressions not just on the patients but on their family and friends.
Hepatitis C, an infectious disease of the liver caused by the hepatitis C virus (HCV), affects 160 million people worldwide. There’s no vaccine for HCV and the few treatments that are available do not work on all variants of the virus. Before scientists can develop potential vaccines and additional therapies they must first thoroughly understand the molecular-level activity that takes place when the virus infects a host cell.
A study suggests that do-it-yourself flu vaccine might be possible. Researchers found that military folks who squirted a nasal vaccine up their noses were as well-protected as others who got it from health workers. The study leader says there is no reason that ordinary people could not be taught to give the vaccine, especially for children who might be less scared if they received it from mom or dad.
Ebola's victims may include a dog named Excalibur. Officials in Madrid got a court order to euthanize the pet of a Spanish nursing assistant with Ebola because of the chance the animal might spread the disease. At least one major study suggests that dogs can be infected with the deadly virus without having symptoms. But whether or how likely they are to spread it to people is less clear.
Until now, researchers searching for compounds that have the potential to become a new HIV drug have been hampered by slow computers and inaccurate prediction models. Now, researchers in Denmark have developed an effective model based on quantum mechanics and molecular mechanics that has found, out of a half-million compounds, 14 of interest in just weeks.
According to two recent studies, viruses can convert their DNA from solid to fluid form, explaining how viruses manage to eject DNA into the cells of their victims. The researchers in one study, which focused on herpes infections, say the discovery was surprising: No one was previously aware of the “phase transition” from solid to fluid form in virus DNA.
Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven’t worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. And the key is in the vaccine’s unique stealthy nanoparticles.
Federal health officials on Tuesday confirmed the first case of Ebola diagnosed in the U.S., a patient who recently traveled from Liberia to Dallas and a sign of the far-reaching impact of the out-of-control epidemic in West Africa. The unidentified patient was critically ill and has been in isolation at Texas Health Presbyterian Hospital since Sunday, officials said.
For decades, researchers have tried to develop broadly effective vaccines to prevent the spread of illnesses such as HIV, malaria and tuberculosis. While limited progress has been made along these lines, there are still no licensed vaccinations available that can protect most people from these devastating diseases. So what are immunologists to do when vaccines just aren't working?
The American strategy on Ebola is two-pronged: step up desperately needed aid to West Africa and, in an unusual step, train U.S. doctors and nurses for volunteer duty in the outbreak zone. At home, the goal is to speed up medical research and put hospitals on alert should an infected traveler arrive.
Malaria threatens more than 40% of the world’s population and kills up to 1.2 million people worldwide each year. Many of these deaths happen in Sub-Saharan Africa in children under the age of five and pregnant woman. The estimates for clinical infection is somewhere between 300 to 500 million people each year, worldwide.
A self-assembling nanoparticle designed by a Univ. of Connecticut (UConn) professor is the key component of a potent new malaria vaccine that is showing promise in early tests. For years, scientists trying to develop a malaria vaccine have been stymied by the malaria parasite’s ability to transform itself and “hide” in the liver and red blood cells of an infected person to avoid detection by the immune system.
Federal researchers next week will start testing humans with an experimental vaccine to prevent the deadly Ebola virus. The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline.
Globally, 22 million infants aren’t receiving basic vaccines and 1.5 million children will die each year from vaccine-preventable diseases before they reach age five. This challenge is further complicated by the fact that most vaccines must be refrigerated, and more than a billion people globally don’t have reliable access to electricity. Vaccination rates are lowest in remote and rural locations. As part of Intellectual Ventures’ Global Good program, Intellectual Venture Labs (IVL) approached Stratos Product Development for help in developing an insulated container to strengthen and extend vaccination services in developing countries.
New research suggests a one-two punch could help battle polio in some of the world's most remote and strife-torn regions: Giving a single vaccine shot to children who've already swallowed drops of an oral polio vaccine greatly boosted their immunity. The World Health Organization officials said the combination strategy already is starting to be used in mass vaccination campaigns in some hard-hit areas.
Scientists are racing to begin the first human safety tests of two experimental Ebola vaccines, but it won't be easy to prove that the shots and other potential treatments in the pipeline really work. There are no proven drugs or vaccines for Ebola, a disease so rare that it's been hard to attract investments in countermeasures. But the current outbreak in West Africa is fueling new efforts to speed Ebola vaccine and drug development.
A federal panel says older Americans should start getting a new vaccine against bacteria that cause pneumonia. The Advisory Committee on Immunization Practices voted Wednesday to recommend a dose of the expensive new shot for people 65 and older. The panel said older adults should still get an older pneumococcal vaccine, too.
The use of an experimental drug to treat two Americans diagnosed with Ebola is raising ethical questions about who gets first access to unproven new therapies for the deadly disease. But some health experts fear debate over extremely limited doses will distract from tried-and-true measures to curb the growing outbreak.
Virologists and biologists in California have identified a highly abundant, never-before-described virus that could play a major role in obesity, diabetes. The virus, named crAssphage, has about 10 times as many base pairs of DNA as HIV and infects one of the most common types of gut bacteria. This phylum of bacteria is thought to be connected with obesity, diabetes and other gut-related diseases.
If you’re allergic to dust mites, help may be on the way. Researchers at the Univ. of Iowa have developed a vaccine that can combat dust-mite allergies by naturally switching the body’s immune response. In animal tests, the nano-sized vaccine package lowered lung inflammation by 83% despite repeated exposure to the allergens.
The most advanced vaccine for dengue only offers modest protection but could still help millions of people avoid the devastating effects of the disease known as "breakbone fever," according to a large trial. There's no treatment for dengue, which causes symptoms including fever, joint pain, headaches and bleeding. About half the world's population is at risk from the mosquito-borne disease, which sickens about 100 million people every year.
- Page 1